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Background: Aβ transport (flux) across the blood-brain barrier (BBB) is thought to contribute to the pathogenesis
of Alzheimer’s disease as well as to elimination of toxic amyloid from the brain by immunotherapy. Several BBB
transporters have been implicated in Aβ exchange between brain parenchyma and the circulation, including efflux
transporters P-glycoprotein/ABCB1 and BCRP/ABCG2. Here we describe an application of in vivo optical imaging
methods to study Aβ transport across the BBB in wild-type or animals deficient in specific efflux transporters.
Methods/Design: Synthetic human Aβ1-40 or scrambled Aβ40-1 peptides were labeled with the near-infrared
fluorescent tracer, Cy5.5. The free tracer or Cy5.5-labeled peptides were injected intravenously into Abcb1-KO or
Abcg2-KO mice or their corresponding wild-type controls. The animals were imaged prospectively at different time
points over a period of 8 hours using eXplore Optix small animal imager. At the end of the observation, animals
were sacrificed by perfusion, their brains were imaged ex-vivo and sectioned for immunofluorescence analyses.
Discussion: After appropriate circulation time, the fluorescence concentration in the head ROI measured in vivo
was close to background values in both wild-type and Abcb1-KO or Abcg2-KO mice injected with either free dye
or scrambled Aβ40-1-Cy5.5. In animals injected with Aβ1-40-Cy5.5, the deficiency in either Abcb1 or Abcg2 resulted in
significant increases in fluorescence concentration in the head ROIs 2 hours after injection compared to wild-type
animals. Fluorescence decay (elimination rate) over 2–8 hours after injection was similar between wild-type
(t1/2 = 1.97 h) and Abcg2
-KO (t1/2 = 2.34 h) and was slightly faster (t1/2 = 1.38 h) in Abcb1
-KO mice. In vivo time-
domain imaging method allows prospective, dynamic analyses of brain uptake/elimination of fluorescently-labeled
compounds, including Aβ. Deficiency of either of the two major efflux pumps, Abcb1 and Abcg2, implicated in Aβ
trafficking across the BBB, resulted in increased accumulation of peripherally-injected Aβ1-40 in the brain.
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Optical imagingBackground
Alzheimer’s disease (AD) is a chronic neurodegenerative
disease characterized, among other neuropathological
features, by the accumulation, aggregation and deposition
of beta-amyloid peptides (Aβ peptides) in the brain [1,2].
Aβ peptides form oligomers, aggregates and plaques
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reproduction in any medium, provided the orneuroinflammation and neurodegenerative pathology in
Alzheimer’s disease [1-4].
Mechanistic studies have generated a substantial body
of evidence that brain accumulation of Aβ peptides is
not solely due to their increased production in the brain,
but also to reduced brain clearance and/or increased
uptake from peripheral circulation [5,6]. Both latter
processes are controlled by the polarized blood-brain bar-
rier (BBB) receptors and transporters [7-10]. Blood-borne
Aβ is taken up into the brain by the luminally-expressed
endothelial receptor for advanced glycation end-productsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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largely mediated by the abluminal low-density lipoprotein
receptor-related protein 1 (LRP1) [5,6,13,14]. A soluble
form of LRP1 (sLRP1) is the major endogenous peripheral
Aβ 'sink' that sequesters some 70 to 90% of plasma Aβ
peptides [5]. Recent evidence also implicated key ABC
family BBB transporters in Aβ trafficking between brain
and circulatory compartments; luminal efflux transporter
ABCG2 has been shown to prevent blood-borne Aβ from
entry into the brain [8,15,16], whereas BBB P-glycoprotein
/ABCB1's role in the brain clearance of Aβ has been
demonstrated in both in vitro and transgenic AD models
[16-20]. It is important to note that shuttling of Aβ across
the BBB occurs by receptor/transporter-mediated pro-
cesses that require the intact tertiary structure of the
peptide that interacts with the carrier receptor(s).
Aβ brain intake and brain clearance have been studied
using radioisotope-labeled Aβ peptides injected sys-
temically or stereotactically into the brain, and by
monitoring their appearance in various compartments,
including cerebral spinal fluid (CSF) [21]. A molecular
imaging tracer, [11C]-Pittsburgh compound B (PiB),
which binds to Aβ plaques, has been used in small-
animal and human PET (positron-emission tomography)
imaging studies to monitor Aβ plaque load and its clear-
ance in response to treatment [22]. The purpose of this
study protocol is to demonstrate the utility of a simple
and accessible in vivo optical imaging method for studying
Aβ trafficking across the BBB in experimental animals in a
dynamic, prospective fashion not achievable with ra-
dioactive tracers. Using this method, we demonstrated
differences in Aβ trafficking across the BBB in animals
deficient in two major ABC efflux pumps, mdr-1 P-
glycoprotein/Abcb1 and Abcg2.Methods and design
Materials
Synthetic human Aβ1-40 and scrambled Aβ40-1 peptides
were purchased from Biopeptides Co., Inc (San Diego, CA,
USA). Cy5.5 labeling kits (Cy5.5™ Mono NHS ester) and
ECL Plus reagent kits were purchased from Amersham
Biosciences/GE Healthcares (Buckinghamshire, UK). A
mouse monoclonal anti-Aβ antibody 6E10 was purchased
from the Covance Inc (Montreal, QC, Canada), and a goat
anti-mouse secondary antibody conjugated with Alexa 568
and a HRP-conjugated donkey anti-mouse IgG antibody
were purchased from the Santa Cruz Biotech Inc
(Santa Cruz, CA, USA). Fluorescein-labeled lectin, Ulex
europeaus agglutinin (UEA-I), was purchased from Vector
Laboratories Inc (Burlington, ON, Canada). Fetal bovine
serum (FBS) was purchased from Hyclone Inc (Logan,
Utah, USA). Dulbecco’s phosphate-buffered saline (1X)
(PBS) was purchased from GIBCO/Invitrogen (InvitrogenInc., Grand Island, NY, USA). Autoradiography films were
purchased from Mandel Scientific (Guelph, ON, Canada).
Aβ peptides preparation and labeling
Aβ1-40 peptide used in this study for optical imaging/
tracking is the most abundant Aβ peptide found in the
cerebral vasculature and is more soluble than Aβ1-42
peptide. Aβ1-40 peptides (1 mg/vial) were dissolved in
250 μL of 10 mM NaOH, and then 12.5 μL of 1 M
HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid] was added to bring the pH to 8.0. The peptides
were divided into 2 tubes (0.5 mg/tube) and kept at −80°C.
Because Aβ peptides are commonly present as beta sheet
structure in solution, Western blot analyses of the mixtures
were performed, and the majority of the peptides (>95%)
were monomers with a small proportion of dimers (data
not shown). Aβ1-40 or scrambled Aβ40-1 peptides (0.5 mg,
molecular weight 4329.86D) were labeled with the near-
infrared fluorescent dye Cy5.5 (molecular weight 1128.42D)
using the labeling kit (Cy5.5™ Mono NHS ester) as per
manufacturer’s instructions [8].
Cy5.5 is a monofunctional dye with absorbance at
675 nm, extinction maximum of 250,000 M-1 cm-1, and
emission maximum of 694 nm. The functional group
commonly used for labelling peptides and proteins is the
primary amino group provided by lysine or the N-
terminal amino group. The labelling with Cy5.5 NHS
ester utilizes acylation reaction at the amino group. The
N-terminal amino group and two lysine residues present
in both Aβ1-40 and scrambled Aβ40-1 peptides may be ac-
cessible to labelling with Cy5.5 dye. Thus, Aβ1-40
peptides can be efficiently labelled with Cy5.5 and then
purified free from unincorporated dye for optical im-
aging. The Cy5.5-labeled peptide can be either injected
into the systemic circulation or into the brain to monitor
its transport across the BBB.
Aβ peptides (0.5 mg peptide) were added to 40 μL of
carbonate buffer (pH 9.1) and 20 μL of Cy5.5 NHS Ester
dye (200 μg in DMSO) and incubated in the dark with
rotation at room temperature for at least 2 h. The mo-
lecular weight of a labeled Aβ peptide is up to 7715 Dal-
ton. The labeled peptides were purified using a column
Microcon Ultracel YM-3 (Regenerated cellulose 3000
MWCO, Millipore Corp., Bedford, MA, USA) to remove
unincorporated Cy5.5. The amount of labeled peptides
was quantified using a BCA Protein Assay kit (Thermo
Scientific, Rockford, IL, USA) following the manufac-
turer’s instructions and the labeling efficiency was
determined by the BioTek FL × 800 microplate reader
(673 nm for excitation and 692 nm for emission). The
labeling efficiency/molar ratio was two-three Cy5.5
molecules per Aβ peptide, and was the same for Aβ1-40
and the scrambled Aβ40-1. The purified Aβ peptides
(100 μg in 100 μL) were diluted with 100 μL saline to a
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mice.
Aβ-Cy5.5 conjugate stability in serum
To evaluate Aβ-Cy5.5 conjugate stability in serum, the
labeled peptide (5-μL volume containing ~1 μg Aβ) was
added to either 35 μL of (non-inactivated) FBS or 35 μL
of 1 × PBS (1: 8 dilution) and incubated at 37°C for 0,
0.5, 1, 2, 4, 6, and 8 hours, respectively. The peptides
(4 μL) from each of the above reactions (40 μL/reaction)
were added to the loading buffer, boiled for 10 min, and
resolved on a 16% Tricine-SDS-PAGE as described [23].
The tricine-SDS-PAGE gel was scanned in the optical
imager; the peptides in the gel were then transferred to a
PVDF membrane for immuno-blotting [8]. A mouse
monoclonal anti-human Aβ antibody 6E10 (1:1000 dilu-
tion) and the secondary HRP-conjugated donkey anti-
mouse IgG antibody (1:5000 dilution) were used for
immunodetection. ECL plus detection reagents were
applied to the blots and the blots were exposed to auto-
radiography films.
Animals
The experiments with animals have been approved by
the Animal Care Committee of the National Research
Council of Canada - Ottawa (NRC). Wild-type (wt), mdr-
1a/b (Abcb1a/b) knockout (Abcb1KO), and Abcg2-KO mice
of FVB background were purchased from the Taconic
Farms Inc (New York, USA) and maintained in the NRC
Animal Facility at Ottawa. Pairs of adult wild-type mice
and Abcb1-KO and pairs of adult wild-type and Abcg2-KO
mice of the same body weight and same sex were matched
for injections and imaging experiments. After initial
testing of fluorescence signal with various injected doses
of Cy5.5-labeld Aβ peptides, the optimal dose selected for
the experiments was 100 μg of labelled peptide in 200-μL
volume. The mice were injected via tail vein with free
Cy5.5 dye (~78 μg in 200 μL volume) or Cy5.5-labeled
Aβ1-40 (100 μg in 200 μL volume) or Aβ40-1 peptides
(100 μg in 200 μL volume) and were imaged in eXplore
Optix 670 (GE Healthcare Systems/ART Inc) at different
time-points after the injection as described below.
Time-domain in vivo optical imaging
One week before the experiments, animals were placed
in cages with bedding that, if ingested, does not produce
in vivo autofluorescence. The animals were anesthetized
with inhaled isoflurane (4% for induction and 1.5% for
maintenance) and the fur was shaved from the head and
dorsal side of the body. The labeled peptides (100 μg) or
Cy5.5 free dye (~78 μg) were injected intravenously (i.v.)
via the tail vein. The animals were imaged at 2, 4, 6, and
8 h post-injection using the time-domain optical imager
eXplore Optix 670 (GE Healthcare Systems/ART Inc).The imaging protocols were described in detail previ-
ously [8,24-27].
Briefly, each animal was positioned on a platform (dor-
sal side facing up) that was then placed on a heated plate
(at 36°C) in the imaging system. The whole-body scan or
selected region of interest (ROI) scan (i.e., head) was
performed as described [25,27]. In all imaging experi-
ments, a 670-nm pulsed laser diode with a repetition
frequency of 80 MHz and a time resolution of 12 ps was
used for excitation. The fluorescence emission at 700 nm
was collected by a highly sensitive photomultiplier tube
offset by 3 mm for diffuse optical topography reconstruc-
tion. The optical imager uses a Time-Correlated Single
Photon Counting (TCSPC) detection system coupled with
a pulsed laser source. Images are built point per point in a
raster scan fashion. The combination of a raster-scanning
approach with a pulsed laser excitation reduces back-
ground and allows for depth probing. A pulsed light
source and time-resolved detection allows the system to
resolve the nanosecond timescale of fluorescence emis-
sion. Each scanned point acquired with the system
contains a photon time-of-flight distribution (also called a
Temporal Point Spread Function or TPSF). Laser power
and counting time per pixel were optimized at 60 mW
and 0.5 seconds, respectively. The values remained con-
stant during the entire experiment. The raster scan inter-
val was 1.5 mm and was held constant during the
acquisition of each frame, and 1,024 points were scanned
for each ROI. The data were thus recorded as TPSF and
the images were reconstructed as fluorescence concen-
tration maps. Average fluorescence concentration data from
ROI placed around the heads were subsequently analyzed
using the software ART Optix Optiview (ART Inc.,
Montreal, QC, Canada). The software normalizes all images
obtained in the same experimental run (i.e., paired animals,
same injected solution) to the same fluorescent scale
(expressed in arbitrary units). After the last scan, the mice
were cardiac-punctured and then perfused transcardially
with 50-mL cold saline with a peristaltic ISMATECH pump
(IDEX Health & Science GmbH. Germany) at 5 mL/min
for 10 min to wash out the remaining blood and circulating
fluorescence. Brains were then extracted and scanned
ex-vivo for fluorescence concentration
Immunohistochemistry
To demonstrate the presence of Aβ peptides in the brain,
the brains extracted at the end of the imaging protocol
were frozen-sectioned at 10 μm and immunostained with a
mouse monoclonal anti-human Aβ antibody 6E10 and a
goat anti-mouse secondary antibody conjugated with Alexa
568 as described [3,4,8]. The sections were also counter-
stained with fluorescein-labeled lectin, Ulex europeaus ag-
glutinin (UEA-I), as described [28] to visualize cerebral
vessels.
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The fluorescent concentrations in mouse brains were
compared by one-way ANOVA followed by Newman-
Keuls post-hoc test.
Results
Is Cy5.5 a substrate for mdr-1 P-glycoprotein or ABCG2?
To enable prospective in vivo optical imaging of the dis-
tribution of peripherally-injected Aβ peptides, the
peptides were labeled with the near-infrared fluorescent
dye Cy5.5. Since the principal aim of the present study
was to monitor brain distribution of Cy5.5-labeled Aβ
peptide in mice lacking major ABC transporters, the
fluorescent tracer itself should not be the substrate for
these transporters. To compare the permeability of BBB
for Cy5.5 in wild-type, Abcb1-KO and Abcg2-KO animals,
equal amounts of Cy5.5 tracer were intravenously injected
into two pairs of wild-type and knockout mice; concentra-
tion of Cy5.5 fluorescence in their heads was determined
by prospective optical imaging between 2 and 8 h after
injection. The plasma half-life of Cy5.5 is about 30 min
and the majority of the dye is cleared from the body in
2 hours. Remaining fluorescence in the head ROI was
close to background and was not different between wild-
type and Abcg2-KO (Figure 1) or Abcb1-KO (not shown)
animals. Data indicate that the BBB in both wt and ABC-
knockout animals is equally restrictive to Cy5.5, consistent
with its molecular weight (1128.42D) and our previous
observation that Cy5.5 can be detected in the brain only
after the BBB breakdown [24,25]. Furthermore, since the
deficiency in either mdr-1 P-glycoprotein (Abcb1) or
Abcg2 has been shown not to affect BBB tight-junctions
/passive permeability [29], the absence of brain accumula-
tion of systemic Cy5.5 in these animals indicated that
Cy5.5 is not a substrate for these transporters and can be
used as fluorescent imaging tracer for Aβ tracking after
systemic injection.Figure 1 Serial images of the concentration of the near-infrared fluor
injection in wild-type and Abcg2-KO mice. Cy5.5 free dye (~78 μg in 200
and 8 h using the eXplore Optix 670. The images shown were analyzed us
per group.Stability of Aβ-Cy5.5 conjugates in serum
The stability of Aβ-Cy5.5 conjugates in serum was
evaluated ex vivo by exposing conjugates to the intact,
non-inactivated FBS or PBS for up to 8 h at 37°C. The
dilutions (1:8 v/v) of the Aβ-Cy5.5 conjugates in FBS
and PBS were adjusted to represent circulatory dilution
after i.v. injection of 200 μL Aβ-Cy5.5 conjugates into
adult mouse. Cy5.5-labeled Aβ peptides resolved on a
tricine-SDS-PAGE gel were imaged in eXplore Optix,
showing the presence of Cy5.5-signal after the exposure
to either FBS or PBS for up to 8 h (Figure 2A).
Immunoblots of the same tricine-SDS-PAGE gels
using 6E10 anti-Aβ antibody (Figure 2B), showed
single bands with similar mobility as unlabeled Aβ.
Although the resolution of gels was not sufficient to
resolve differences in MW (1–3 kD) between Cy5.5-
labeled and unlabeled Aβ, no appreciable reductions
of intact Aβ peptide bands were observed after incu-
bation in either PBS or FBS, suggesting that Aβ-Cy5.5
conjugates were mostly intact in the serum ex vivo up
to 8 hours.
Brain accumulation of Aβ1-40 and scrambled Aβ40-1
The biodistribution and systemic elimination (pharma-
cokinetics) of Aβ-Cy5.5 was evaluated by serial whole-
body imaging after i.v. injection of labeled peptides into
wild-type and transporter knockout animals. Our recent
work demonstrated that the fluorescence residence time
evaluated by whole-body imaging correlates closely with
the circulation half-life of injected Cy5.5-labeled proteins
[30]. The elimination kinetics of injected Aβ-Cy5.5 were
similar in the wild-type and Abcg2-KO (Figure 3A) and
Abcb1-KO (not shown), showing almost complete dis-
appearance of fluorescence from the body between 2 h
and 4 h after injection. The only discernible difference
was the increased head fluorescence signal in transporter
KO animals (Figure 3A).escent tracer Cy5.5 in the head region (ROI) after intravenous
μL saline) was injected i.v. and mice were repeatedly imaged at 2, 4, 6
ing ART Optix Optiview software and are representative of 4 animals
Cy5.5-Aβ in PBS Cy5.5-Aβ in FBS
10kD
0 0.5 1 2 4 6 8 0 0.5 1 2 4 6 8C
0 0.5 1 2 4 6 8 0 0.5 1 2 4 6 8
A
B
Figure 2 The stability of Cy5.5-labeled Aβ1-40 peptide in serum ex vivo. Cy5.5-labeled Aβ1-40 peptides were incubated in either phosphate
buffered saline (PBS) or fetal bovine serum (FBS) at 37°C for indicated periods of time, resolved on a 16% Tricine-SDS-PAGE gel, imaged using
eXplore Optix optical imager (A), and then blotted to PVDF membrane and probed with the anti-human Aβ antibody 6E10 (B). The lane C























Figure 3 Serial concentration images of Abcg2-KO and wild-type mice injected i.v. with either Cy5.5-labeled scrambled Aβ40-1 or Aβ1-40
peptides. The peptides (100 μg in 200 μL volume) were injected i.v. and whole body and head ROIs of animals were imaged at 2, 4, 6, and 8 h
using the eXplore Optix 670. Panel A shows the whole body (dorsal) images of wild-type and Abcg2-KO mice 2 and 4 h after i.v. injection of
Cy5.5- Aβ1-40. Panel B shows head ROI fluorescence concentration images over time in wild-type mice injected with scrambled Aβ40-1, and
Abcg2-KO mice injected with either Cy5.5-labeled scrambled Aβ40-1 or with Cy5.5-labeled Aβ1-40 peptide. The images shown were analyzed with
ART Optix Optiview software and are representative of 4 animals per group.
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mine whether the observed accumulation of Cy5.5-la-
beled Aβ1-40 in the head region of KO animals was Aβ1-
40. Therefore, Cy5.5-labeled scrambled Aβ40-1 was used
in comparative experiments. After systemic injections of
the equimolar concentrations (and equal fluorescence
intensity) of Cy5.5-labeled peptides, the imaged head
concentrations of scrambled Aβ40-1 were similar in wild-
type and Abcg2-KO (Figure 3B) or Abcb1-KO mice (data not
shown), while concentrations of Aβ1-40 were consistently
higher than those of scrambled Aβ40-1 in Abcg2
-KO mice
(Figure 3B). These observations suggested that only
Aβ1-40, but not its scrambled version, is trafficked from
the circulation into the brain, likely through binding to
specific brain endothelial receptors/transporters.
Brain accumulation of blood-borne Aβ1-40 peptides in
Abcg2- or Abcb1- knockout animals
To evaluate whether there are differences in brain accu-
































Figure 4 Fluorescence concentration images of the head ROI after i.v
wild-type or Abcg2-KO mice obtained by eXplore Optix 670. Panel A sh
4, 6, and 8 h after Cy5.5-Aβ1-40 injection. The data are normalized to wild-ty
fluorescence concentration changes (means ± SEM from four paired sets of
expressed as percent of fluorescence concentration normalized to 2-h wt a
were compared Newman-Keuls post-hoc test (for wild-type vs. Abcg2-KO m
8 h vs. 8 h p > 0.05; for Abcg2-KO vs. Abcg2-KO mice: 2 h vs. 4 h p < 0.01, 2
mice: 2 h vs. 4 h p < 0.05, 2 h vs. 6 h p < 0.05, and 2 h vs. 8 h p < 0.01). Pan
Cy5.5-Aβ1-40 injection by transcardial perfusion.ABC-transporter-deficient animals, four pairs of adult
wild-type and Abcb1-KO mice and five pairs of adult
wild-type and Abcg2-KO mice were intravenously in-
jected via the tail vein with the same amount of Cy5.5-
labeled Aβ1-40 peptides and imaged prospectively over
2–8 h period. At the end of the protocol, mice were
perfused with 50-mL cold saline and their brains were
also imaged ex vivo.
The circulation half-life of injected 125I-Aβ peptides is
about 35–45 min [31,32]. Therefore, the initial imaging
time point of 2 hours (3–4 half-lives) was chosen to
allow for a substantial clearance of the tracer from the
circulation (also shown in Figure 3A). Therefore, fluores-
cence concentrations measured in the head ROI are
assumed to represent mostly non-circulatory tracer, ei-
ther bound/internalized into the brain vessels or
transported into the brain parenchyma.
Comparisons of fluorescent concentrations in the head
ROIs indicated that the fluorescence concentration of





. injection of 100-μg Cy5.5-labeled Aβ1-40 peptide into either
ows representative serial concentration images of the head ROI at 2,
pe animals at 2 h as 100%. Panel B shows time-dependent
experiments) in wild-type and Abcg2-KO animals. The data was
nimals and analyzed using one-way ANOVA and individual groups
ice: 2 h vs. 2 h p < 0.01, 4 h vs. 4 h p < 0.05, 6 h vs. 6 h p > 0.05, and
h vs. 6 h p < 0.001, and 2 h vs. 8 h p < 0.001; for wild-type vs. wild-type
el C shows ex-vivo brain images from animals sacrificed 8 h after the
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(Figure 4A, B). However, fluorescence decay curves over
2–8 h (analyzed using one-phase exponential decay)
indicated similar decay dynamics in Abcg2-KO mice (t1/2 =
2.34 h) compared to wild-type (t1/2 = 1.97 h). Imaging of
perfused brains ex vivo (Figure 4C), indicated that brain
fluorescence levels remained elevated in Abcg2-KO mice in
comparison to wild-type animals 8 h after injection.
The head fluorescence concentrations in Abcb1-KO
mice was also significantly higher than in wild-type mice
at the outset of imaging measurements (2 hours)
(124.2% in Abcb1-KO mice normalized to wild-type mice
at 2 h as 100%) (Figure 5A, B). The fluorescence concen-
tration ‘decay’ over 2–8 h, showed slightly faster decay
dynamics in Abcb1-KO mice (t1/2 = 1.38 h) compared to
wt-type (t1/2 = 1.97 h) (Figure 5B). At the end of the
imaging protocol perfused brains were imaged ex-vivo
(Figure 5C), confirming that the fluorescence concentra-
tion differences observed in vivo were not due to circu-





























Figure 5 Fluorescence concentration images of the head ROI after i.v
wild-type or Abcb1-KO mice obtained by eXplore Optix 670. Panel A sh
4, 6, and 8 h after Cy5.5-Aβ1-40 injection. The data are normalized to wild-ty
fluorescence concentration changes (means ± SEM from four paired sets of
expressed as percent of fluorescence concentration normalized to 2-h wt a
were compared Newman-Keuls post-hoc test (for wild-type vs. Abcb1-KO m
8 h vs. 8 h p > 0.05; for Abcb1-KO vs. Abcb1-KO mice: 2 h vs. 4 h p < 0.05, 2
mice: 2 h vs. 4 h p > 0.05, 2 h vs. 6 h p < 0.05, and 2 h vs. 8 h p < 0.001). Pa
Cy5.5-Aβ1-40 injection by transcardial perfusion.Immunohistochemistry detects Aβ peptides in mouse
brain
To determine whether measured Cy5.5 fluorescence in im-
aging experiments originated from the intact Cy5.5-Aβ1-40
conjugates rather than from the proteolytically-degraded
fragments or dye alone, Aβ peptides were detected in the
brain tissues of wild-type and Abcg2-KO mice using an anti-
Aβ antibody, 6E10. Brain sections probed with secondary
antibody only (Figure 6A & B) showed no detectable signal.
The immunoreactive Aβ (red) was detected in brain
sections of both wild-type and Abcg2-KO animals injected
with Cy5.5-labeled Aβ1-40 peptides (Figure 6C & D). Aβ
was observed co-localizing with brain vessels as well as
within brain parenchyma (Figure 6E & F).
6E10 antibody recognizes human, but not murine
(endogenous) form of Aβ peptides. In our previous study
[33] investigating the expression of Aβ1-40 and Aβ1-42 in
the brains of wild-type, Abcg2-KO, Tg-SwDI, and double
transgenic Tg-SwDI/Abcg2-KO mice up to 15 months of
age, murine forms of Aβ peptides were below detection6 h 8 h
C
Abcb1KO Wild-type
. injection of 100-μg Cy5.5-labeled Aβ1-40 peptide into either
ows representative serial concentration images of the head ROI at 2,
pe animals at 2 h as 100%. Panel B shows time-dependent
experiments) in wild-type and Abcb1-KO animals. The data was
nimals and analyzed using one-way ANOVA and individual groups
ice: 2 h vs. 2 h p < 0.05, 4 h vs. 4 h p > 0.05, 6 h vs. 6 h p > 0.05, and
h vs. 6 h p < 0.01, and 2 h vs. 8 h p < 0.001; for wild-type vs. wild-type











WT mice Abcg2-KO mice
D
F
Figure 6 Aβ1-40 immunohistochemistry in brain sections using a mouse monoclonal anti-Aβ antibody 6E10. The wild-type and Abcg2
-KO
mice were injected with 100 μg Cy5.5-labeled human Aβ1-40 peptides and brain tissues were collected 8 h post-injection. Brain sections were
incubated with either the secondary antibody alone (panels A & B) or 6E10 followed with the Alexa 568 (red)-conjugated secondary antibody
(panels C & D) and were co-stained with UEA-I (green) to visualize cerebral vessels (panels E & F). Images (20 ×magnifications) are representative
of results obtained from 3 animals in each group.
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human forms were detected in Tg-SwDI, and double
transgenic Tg-SwDI/Abcg2-KO mice. Therefore, the pres-
ence of immunoreactive Aβ in the mouse brain after i.v.
injection of Cy5.5-labeled human Aβ peptides suggested
that these peptides were blood-borne and confirmed that
at least a portion of imaging signal originated from
intact Aβ-Cy5.5 conjugates.
Discussion
This study describes the application of prospective
in vivo optical imaging protocols to study brain accumu-
lation of systemically injected Aβ peptides in wild-type
and animals deficient in specific transporters previously
implicated in Aβ transport across the blood-brain
barrier.
Radio-labeled [125I]-or [3H]-Aβ peptides have been
used to study their BBB transport in animal models. The
labelled peptides are either injected intravenously to
analyze brain uptake or intra-cerebrally to investigatetheir clearance from the brain; animals are sacrificed at
different time points and the radioactivity is determined
in desired compartments. In vivo molecular imaging
approaches that ‘track’ Aβ peptides non-invasively are
dynamic methods that can be used for assessing Aβ
levels in response to treatments. Notably, PET imaging
with [C11]-PiB [N-methyl-[11C]2-(4-methylaminophenyl)-
6-hydroxybenzothiazole] has been used for quantitative
assessment of brain Aβ load in Alzheimer’s patients [34]
and in APP/PS1 mouse [22]. Apart from requiring ‘on-
site’ radioisotope labeling and access to expensive PET
equipment, this approach is not applicable for ‘tracking’
peripheral Aβ peptides. Optical molecular imaging/
tracking of Aβ peptides functionalized with the near-
infrared imaging tracer is a viable alternative that can pro-
vide high sensitivity in experimental setting, although it
does not have the quantification capabilities of PET.
Among in vivo optical imaging systems, time-domain
optical imaging has a clear advantage over Continuous
Wavelength (CW) systems in that its pulsed laser source
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tissues. In contrast to CW systems where emitted light is
collected by a CCD camera that cannot resolve the depth
of the signal, with time-resolved imaging platform each
collected photon retains time-of-flight distribution (also
called a Temporal Point Spread Function or TPSF) from
which depth (optical tomography), fluorescence concen-
tration and fluorescence lifetime can be extracted [24-27].
This and other studies [35,36] have shown that this
imaging method is a useful non-invasive approach to
investigate Aβ transport, distribution, and clearance from
the brain that complements other imaging approaches.
The aberrant transport and clearance of Aβ peptides
across the BBB, mediated by a spectrum of receptors
and transporters including RAGE, LRP-1, and members
of ABC family, contributes to Aβ accumulation in the
brain and in the cerebral vasculature [7,37,38]. ABC
family members MDR-1 P-glycoprotein/ABCB1 and
ABCG2/BCRP are two major drug efflux transporters
located at the luminal surface of the BBB [39,40]. In
mice, mdr-1a (Abcb1a) is the primary drug efflux trans-
porter expressed at the BBB; while mdr-1b (Abcb1b) is
the main isoform detected in the brain parenchyma [41].
Murine mdr-1 P-glycoprotein is encoded by both mdr-
1a (Abcb1a) and mdr-1b (Abcb1b), which share 90%
sequence homology and have 80% homology to human
MDR1 (ABCB1). The mdr-1a/b (Abcb1a/b) double
knockout completely eliminates mdr-1-mediated trans-
port activity at the BBB. Several published studies
[8,15-20] presented the evidence that inhibition or defi-
ciency of Abcg2 or mdr-1 P-glycoprotein increases Aβ
intake in cell models and reduces brain Aβ clearance in
animal models.
To further evaluate the roles of Abcb1 and Abcg2 in
Aβ trafficking across the BBB, we developed the non-
invasive optical imaging method for ‘tracking’ systemic-
ally injected fluorescently-labeled Aβ peptides in Abcb1-KO
and Abcg2-KO mice. For the purpose of in vivo tracking Aβ
peptides were conjugated to the near-infrared optical fluor-
escence tracer Cy5.5. Since Aβ degrading proteases includ-
ing insulin degrading enzyme (IDE), angiotensin converting
enzyme (ACE) and neprilysin [42,43] are active in the blood
and can contribute to Aβ degradation, the stability of
Cy5.5-Aβ conjugates in serum over 8 hours was confirmed
ex-vivo, proving that the optical signal in imaging ex-
periments originated predominantly from intact Cy5.5-Aβ
conjugates. Imaging assessment of the whole-body
biodistribution and elimination kinetics of Cy5.5-Aβ
peptides, demonstrated similar elimination kinetics in
wild-type and KO animals; the majority of peripheral
tracer was eliminated by 2–4 h after the injection. This is
in agreement with previous studies that reported the cir-
culation half-life of injected [125I]-Aβ peptides of about
35–45 min; ~81% of the injected Aβ was cleared fromblood by 60 min after administration in adult monkey
[32,33,44].
Head ROI imaging protocols were initiated 2 hours
after tracer injection, allowing 3–4 circulation half-lives;
therefore, measured head fluorescence concentration
was primarily indicative of the brain-accumulated/
retained tracer, with small contribution of circulating
tracer. In both Abcb1-KO and Abcg2-KO animals, brain
tracer concentration was higher than in the wild-type
animals at 2 hours, suggesting that any of the following
processes or their combination might have been altered in
knockout animals: a) the rate of Aβ brain influx was
increased; b) the rate of Aβ brain elimination was slower;
and c) Aβ binding/uptake into brain vessels was increased.
Based on the current data, we cannot exclude any of these
processes being responsible for the observed tracer con-
centration differences at 2 hours after injection. However,
given the relatively short circulation half-life of Aβ, we can
assume that imaging measurements between 2 and 8 hours
after injection reflect predominantly brain elimination kin-
etics of Aβ. Brain-injected [125I]-Aβ1-40 peptide has been
shown to clear rapidly via receptor-mediated transport
with t1/2 of 25 minutes [45]. A single photon emission
computed tomography (SPECT) study in squirrel mon-
keys [46], demonstrated a bi-phasic brain clearance of
intracerebrally microinfused [123I]-Aβ1-40, with short t1/2
ranging from 1.1 ~ 2.7 hours and accompanying plasma
appearance of [123I]-Aβ1-40, suggesting active brain-to-blood
transport. Comparisons of Aβ fluorescence decay curves
between 2 and 8 h in wild-type and ABC-transporter
knock-out animals indicated similar fluorescence decay
(elimination) kinetics within the range of clearance rates
described by Bading et al [46]. Due to limited number of
imaging time-points and the study design, it was not
possible to discern whether the observed elimination kin-
etics of Aβ are due to active reverse transport across the
BBB or to the interstitial fluid bulk-flow clearance.
Whereas lack of Abcg2 in this study did not appear to
affect the rate of Aβ elimination from the brain, it
resulted in higher initial accumulation of injected Aβ,
suggesting that it has a role in either limiting brain
access of circulating Aβ or mediating fast brain elimination
phase of Aβ, or both. In agreement with our observations,
a recent study [15] using the in situ brain perfusion tech-
nique showed that GF120918, a dual inhibitor of Abcb1
and Abcg2, strongly enhanced the uptake of [3H]-Aβ1-40 in
the brains of Abcb1-deficient mice, but not in the brains of
Abcb1/Abcg2-deficient mice. ABCG2 is up-regulated in
human AD brain with cerebral amyloid angiopathy (CAA)
[8] where it modulates Aβ-induced vascular oxidative
stress [33,47].
Similarly, the deficiency of mdr-1/P-glcoprotein sig-
nificantly increased brain accumulation of systemically
injected Aβ but also slightly accelerated its elimination
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previously reported studies. Deposition of Aβ peptides has
been found to inversely correlate with MDR-1 P-
glycoprotein/ABCB1 expression in the brains of elderly
non-demented humans as well as in the brains of
Alzheimer’s patients [37,48,49]. In addition, Aβ was found
to down-regulate BBB mdr-1 P-glycoprotein (Abcb1) ex-
pression in mice [50]. Cirrito and colleagues [17]
demonstrated that Aβ removal from the brain was par-
tially mdr-1-dependent in mdr-1a/b KO mice. Further-
more, restoration of mdr-1 P-glycoprotein/Abcb1 at the
BBB by PXR (Pregnane X Receptor) agonist reduced brain
Aβ load in a mouse model of Alzheimer's disease [18].
The definitive interpretation of data provided in this
study is confounded by possible activation of compensa-
tory mechanisms in knock-out animals. For example, the
Abcb1/P-glycoprotein-null mice were found to have
lower brain expression of LRP-1 compared to wild-type
mice [17]. We found no compensatory changes in
Abcb1a/mdr-1a and Abcb1b/mdr-1b expression in the
brains of Abcg2-KO mice (data not shown); however, we
cannot ascertain whether other Aβ transporters (i.e.,
RAGE, LRPs) were specifically affected in brain endothe-
lial cells in Abcb1- or Abcg2-KO animals.
Pharmacological studies using selective inhibitors of BBB
transporters in cell systems [15,20] provided strong evi-
dence that both ABCB1/MDR-1 P-glycoprotein and
ABCG2 have the capacity to interact with and shuttle Aβ
across cellular membranes. In vivo imaging studies, includ-
ing ours presented here, support this notion and provide
means for dynamic analyses of integrative influences of
BBB transporters on Aβ trafficking in and out of the brain.
In summary, this study protocol describes potential
application of time-domain prospective in vivo imaging
in assessing BBB trafficking of systemically injected
compounds, including Aβ peptides, labeled with near-
infrared fluorescent imaging tracers. The protocol is par-
ticularly useful in assessing BBB trafficking of such
compounds in animals exhibiting modifications of vari-
ous BBB transporters, such as for example gene knock-
out or over-expression of ABC-family of efflux pumps.
Similarly, this imaging method can be used to evaluate
kinetics of brain elimination of intra-cerebrally-injected
compounds as recently described in our study on FcRn-
mediated brain elimination of fluorescently-labeled
macromolecules [51].
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